Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q15409405> ?p ?o }
Showing triples 1 to 24 of
24
with 100 triples per page.
- Q15409405 subject Q4925926.
- Q15409405 subject Q7064899.
- Q15409405 abstract "Encorafenib, also known as LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis, is in phase III clinical trials, and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans.".
- Q15409405 atcPrefix "None".
- Q15409405 iupacName "Methyl[(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate".
- Q15409405 thumbnail LGX818_structure.svg?width=300.
- Q15409405 wikiPageWikiLink Q17853226.
- Q15409405 wikiPageWikiLink Q180614.
- Q15409405 wikiPageWikiLink Q19903515.
- Q15409405 wikiPageWikiLink Q247556.
- Q15409405 wikiPageWikiLink Q4925926.
- Q15409405 wikiPageWikiLink Q507154.
- Q15409405 wikiPageWikiLink Q7064899.
- Q15409405 wikiPageWikiLink Q7180990.
- Q15409405 atcPrefix "None".
- Q15409405 iupacName "Methyl [-1-{[4--2-pyrimidinyl]amino}-2-propanyl]carbamate".
- Q15409405 type ChemicalSubstance.
- Q15409405 type Drug.
- Q15409405 type ChemicalObject.
- Q15409405 type Thing.
- Q15409405 type Q8386.
- Q15409405 comment "Encorafenib, also known as LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis, is in phase III clinical trials, and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans.".
- Q15409405 label "LGX818".
- Q15409405 depiction LGX818_structure.svg.